These innovative products leverage genetically targeted technologies and raise key regulatory and policy questions that our panelists will explore. This conversation will:

• Clarify how innovative biotechnologies that leverage RNA are classified.
• Explore the current development landscape for RNA-based therapies.
• Address how the commercialization environment affects RNA products relative to other innovative biotechnologies.
• Offer forward-looking perspectives on patient access and policies influencing emerging therapies.
• Learn which diseases with unmet needs will benefit from Genetically Targeted Therapies (or RNA-based therapies.)

In May, Avalere produced a report focused on the future development for RNA-based therapies as a class of medications. Read more here:  Overview and Outlook for RNA-Based Therapies

Panelist views are their own – they do not represent the views or positions of Avalere or Eli Lilly.